James Chmiel, M.D.
Associate Professor
james.chmiel@UHhospitals.org
Rainbow Babies & Childrens
(216) 844 3267 Phone
(216) 844 5916 Fax
Biography
Dr. Chmiel received his M.D. and M.P.H. in Epidemiology, from the University of Michigan in 1991. He worked as a resident in Pediatrics in Children's Memorial Hospital in Chicago until 1994. Dr. Chmiel then joined the Pediatrics Pulmonology group at Case Western Reserve as a fellow from 1995 to 98, where he was promoted to Instructor and then Assistant Professor of Pediatrics in 2001. In 2008, he was promoted to Associate Professor. He became Fellowship Program Director in 2001, the Associate Director of the LeRoy W. Matthews Cystic Fibrosis Center Center in 2004, and the Director of Clinical Affairs in 2007.
Research Interests
Dr. James Chmiel’s research involves understanding the inflammatory response of the lung, particularly as it relates to asthma and cystic fibrosis and the impact of anti-inflammatory therapeutics upon this response. Dr. Chmiel participates in both basic science and clinical research projects. His basic science research focuses on studying the link between the mutant cystic fibrosis gene in bone-marrow-derived cells and the development of the pulmonary inflammatory response in cell culture and animal models. Dr. Chmiel participates in both independent and multi-center clinical trials. Dr. Chmiel is a Co-Investigator in the National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium. In addition, Dr. Chmiel is currently interested in evaluating outcome measures for measuring the inflammatory response in CF patients. Studies are underway evaluating the utility of induced sputum, infant pulmonary function tests, and bronchoscopy with bronchoalveolar lavage as methods of characterizing the patient’s response to anti-inflammatory medications, such as ibuprofen and simvastatin. The ultimate goal of all of these studies is to develop safer, more effective anti-inflammatory therapeutics for the treatment of asthma and CF lung disease.
Publications
Chmiel JF, Konstan MW
"Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent"
Treat Respir Med. 2005;4(4):255-73
Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML
"Inflammatory & microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis"
Am J Respir Crit Care Med. 2003 Dec 15;168(12):1471-5
Chmiel JF, Davis PB
"State of the Art:Why do lungs of patients with cystic fibrosis become infected and why can't they clear the infection?"
Respir Res. 2003 Aug 27;4(1):8
Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Lester Kirchner H, Berger M
"Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice"
Am J Respir Crit Care Med. 2002 Apr 15;165(8):1176-81
Chmiel JF, Konstan MW, Knesebeck JE, Hilliard JB, Bonfield TL, Dawson DV, Berger M
"IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice"
Am J Respir Crit Care Med. 1999 Dec;160(6):2040-7
Chmiel JF, Drumm ML, Konstan MW, Ferkol TW, Kercsmar CM
"Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis"
Pediatrics. 1999 Apr;103(4 Pt 1):823-6
|
